Home » TAIGEN BIOTECHNOLOGY ANNOUNCES STRATEGIC AGREEMENT WITH PROCTER & GAMBLE
TAIGEN BIOTECHNOLOGY ANNOUNCES STRATEGIC AGREEMENT WITH PROCTER & GAMBLE
TaiGen Biotechnology has announced the signing of
a strategic alliance relationship with Procter & Gamble Pharmaceuticals
(P&GP) to further the development and commercialization of a novel non-flourinated
quinolone antibiotic, invented by P&GP. Under the terms of the agreement,
TaiGen will be responsible for conducting Phase Ib and Phase II development
of the compound to meet worldwide regulatory standards.
Yahoo
News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct